A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Fisman, Enrique Z ^a,b   Tenenbaum, Alexander ^a,b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b Cardiovascular Diabetology Research Foundation   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALEGLITAZAR; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; BEZAFIBRATE; BIGUANIDE; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FUROSEMIDE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HOMOCYSTEINE; INCRETIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; NIFEDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; POTASSIUM CHANNEL; PRAMLINTIDE; QUINIDINE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; INSULIN;

ABDOMINAL PAIN; APPETITE; BINDING AFFINITY; BLOOD PRESSURE; CARDIAC PATIENT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHANNEL GATING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BINDING; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG SAFETY; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEMODILUTION; HORMONE ACTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; LACTIC ACIDOSIS; LIPID METABOLISM; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN; ANIMAL; METABOLISM; SURVIVAL RATE;

ANIMALS; CARDIOVASCULAR AGENTS; DIABETES MELLITUS, TYPE 2; HEART DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; SURVIVAL RATE;

EID: 68849088748     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-38     Document Type: Review

References (110)

1. Inzucchi SE Sherwin RS The prevention of type 2 diabetes mellitus Endocrinol Metab Clin North Am 2005, 34:199-219. 15752928
2. Meinert CL Knatterud GL Prout TE Klimt CR A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results Diabetes 1970, 19(Suppl):789-830.
3. Smits P Thien T Cardiovascular effects of sulphonylurea derivatives. Implication for the treatment of NIDDM? Diabetologia 1995, 38:116-121. 7744216
4. Brady PA Terzic A The sulfonylurea controversy: More questions from the heart J Am Coll Cardiol 1998, 31:950-956. 9561992
5. Innerfield RJ Metformin-associated mortality in U.S. studies N Engl J Med 1996, 334:1611-1613. 8628355
6. Misbin RI Green L Stadel BV Gueriguian JL Gubbi A Fleming GA Lactic acidosis in patients with diabetes treated with metformin N Engl J Med 1998, 338:265-266. 9441244
7. Fisman EZ Tenenbaum A Benderly M Goldbourt U Behar S Motro M Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up Cardiology 1999, 91:195-202. 10516414
8. Consensus Statement The pharmacological treatment of hyperglycemia in NIDDM Diabetes Care 1996, 19(Suppl I):S54-S61.
9. Nathan DM Some answers, more controversy, from UKPDS Lancet 1998, 352:832-833. 9742972
10. Wright A Burden AC Paisey RB Cull CA Holman RR Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) Diabetes Care 2002, 25:330-336. 11815505
11. Adams JF Clark JS Ireland JT Kesson CM Watson WS Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy Diabetologia 1983, 24:16-18. 6825978
12. Mayer EL Jacobsen DW Robinson K Homocysteine and coronary atherosclerosis J Am Coll Cardiol 1996, 27:517-527. 8606260
13. Goldner MG Knatterud GL Prout TE Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. III. Clinical implication of UGDP results JAMA 1971, 218:1400-1410. 4941698
14. Marchetti P Navalesi R Pharmacokinetic-pharmacodynamic relationships of oral hypoglycemic agents: An update Clin Pharmacokinet 1989, 16:100-128. 2656043
15. Eurich DT Majumdar SR McAlister FA Tsuyuki RT Johnson JA Improved clinical outcomes associated with metformin in patients with diabetes and heart failure Diabetes Care 2005, 28:2345-2351. 16186261
16. Johnson JA Simpson SH Toth EL Majumdar SR Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes Diabet Med 2005, 22:497-502. 15787679
17. Rosenstock J Samols E Muchmore DB Schneider J Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group Diabetes Care 1996, 19:1194-1199. 8908379
18. Duncker DJ van Zon NS Altman JD Pavek DJ Bache RJ Role of K+ ATP channels in coronary vasodilation during exercise Circulation 1993, 88:1245-1253. 8353886
19. Cole WC Mc Pherson CD Sontag D ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage Circ Res 1991, 69:571-581. 1908354
20. Toombs CF McGee DS Johnston WE Vinten-Johansen J Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia Circulation 1992, 86:986-994. 1516210
21. Ballagi-Pordány G Köszeghy A Koltai MZ Aranyi Z Pogátsa G Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds Diabetes Res Clin Pract 1990, 8:109-114. 2106423
22. Grover GJ Sleph PG Dzwonick BS Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interactions with adenosine A1-receptors Circulation 1992, 86:1310-136. 1394937
23. Garratt KN Brady PA Hassinger NL Grill DE Terzic A Holmes DR Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J Am Coll Cardiol 1999, 33:119-124. 9935017
24. Klepzig H Kober G Matter C Luus H Schneider H Boedeker KH Kiowski W Amann FW Gruber D Harris S Burger W Sulfonylureas and ischemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide Eur Heart J 1999, 20:439-446. 10213347
25. Fuhlendorff J Rorsman P Kofod H Brand CL Rolin B MacKay P Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes Diabetes 1998, 47:345-351. 9519738
26. Hu S Wang S Dunning BE Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: Comparison to sulfonylureas and repaglinide Int J Exp Diabetes Res 2001, 2:63-72. 2478524 12369728
27. Fleming A FDA approach to the regulation of drugs for diabetes Am Heart J 1999, 138(5 Pt 1):S339-S345
28. Hueb W Uchida AH Gersh BJ Betti RT Lopes N Moffa PJ Ferreira BM Ramires JA Wajchenberg BL Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris Coron Artery Dis 2007, 18:55-59. 17172931
29. Duffy NA Green BD Irwin N Gault VA McKillop AM O'Harte FP Flatt PR Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1 Eur J Pharmacol 2007, 568:278-286. 17573070
30. Lebovitz HE Differentiating members of the thiazolidinedione class: A focus on safety Diabetes Metab Res Rev 2002, 18(Suppl 2):S23-S29. 11921435
31. Saltiel AR Olefsky JM Thiazolidinediones in the treatment of insulin resistance and type II diabetes Diabetes 1996, 45:1661-1669. 8922349
32. Duval C Chinetti G Trottein F Fruchart JC Staels B The role of PPARs in atherosclerosis Trends Mol Med 2002, 8:422-430. 12223313
33. DeFronzo RA Pharmacologic therapy for type 2 diabetes Ann Intern Med 1999, 131:281-303. 10454950
34. Bakris G Viberti G Weston WM Heise M Porter LE Freed MI Rosiglitazone reduces urinary albumin excretion in type 2 diabetes J Hum Hypertens 2003, 17:7-12. 12571611
35. Haffner SM Greenberg AS Weston WM Chen H Williams K Freed MI Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus Circulation 2002, 106:679-684. 12163427
36. Goetze S Bungenstock A Czupalla C Eilers F Stawowy P Kintscher U Spencer-Hansch C Graf K Nurnberg B Law RE Fleck E Grafe M Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands Hypertension 2002, 40:748-754. 12411472
37. Nisoli E Carruba MO Tonello C Macor C Federspil G Vettor R Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion Diabetes 2000, 49:319-324. 10868951
38. Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007, 356:2457-2471. 17517853
39. Home PD Pocock SJ Beck-Nielsen H Curtis PS Gomis R Hanefeld M Jones NP Komajda M McMurray JJ RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial Lancet 2009, 373:2125-2135. 19501900
40. Komajda M Curtis P Hanefeld M Beck-Nielsen H Pocock SJ Zambanini A Jones NP Gomis R Home PD RECORD Study Group Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/ sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) Cardiovasc Diabetol 2008, 7:10. 2390513 18435852
41. Dormandy JA Charbonnel B Eckland DJ Erdmann E Massi-Benedetti M Moules IK Skene AM Tan MH Lefèbvre PJ Murray GD Standl E Wilcox RG Wilhelmsen L Betteridge J Birkeland K Golay A Heine RJ Korányi L Laakso M Mokán M Norkus A Pirags V Podar T Scheen A Scherbaum W Schernthaner G Schmitz O Skrha J Smith U Taton J PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial Lancet 2005, 366:1279-1289. 16214598
42. Wilcox R Kupfer S Erdmann E PROactive Study investigators Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10) Am Heart J 2008, 155:712-717. 18371481
43. Deeg MA Buse JB Goldberg RB Kendall DM Zagar AJ Jacober SJ Khan MA Perez AT Tan MH GLAI Study Investigators Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia Diabetes Care 2007, 30:2458-2464. 17595355
44. Rattinger G Bero L Factors associated with results and conclusions of trials of thiazolidinediones PLoS One 2009, 4:6. e5826 2688752 19503811
45. Chiasson JL Josse RG Gomis R Hanefeld M Karasik A Laakso M STOP-NIDDM Trail Research Group Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial Lancet 2002, 359:2072-2077. 12086760
46. Fisman EZ Motro M Tenenbaum A Boyko V Mandelzweig L Behar S Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: A marker for a worse prognosis Am Heart J 2001, 141:485-490. 11231448
47. Tenenbaum A Motro M Fisman EZ Boyko V Mandelzweig L Reicher-Reiss H Graff E Brunner D Behar S Clinical impact of borderline and undiagnosed diabetes mellitus in patients with coronary artery disease Am J Cardiol 2000, 86:1363-1366. 11113414
48. Kawamori R Tajima N Iwamoto Y Kashiwagi A Shimamoto K Kaku K Voglibose Ph-3 Study Group Voglibose for prevention of type 2 diabetes mellitus: A randomised, double-blind trial in Japanese individuals with impaired glucose tolerance Lancet 2009, 373:1607-1614. 19395079
49. Moritoh Y Takeuchi K Hazama M Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice J Pharmacol Exp Ther 2009, 329:669-676. 19208898
50. Narita T Katsuura Y Sato T Hosoba M Fujita H Morii T Yamada Y Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients Diabet Med 2009, 26:187-188. 19236625
51. Turner RC Cull CA Frighi V Holman RR Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes: progressive requirement for multiple therapies (UKPDS 49). UK Diabetes Prospective Study (UKPDS) Group JAMA 1999, 281:2005-2012. 10359389
52. Fisman EZ Tenenbaum A Boyko V Benderly M Adler Y Friedensohn A Kohanovski M Rotzak R Schneider H Behar S Motro M Oral antidiabetic treatment in patients with coronary disease: Time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up Clin Cardiol 2001, 24:151-158. 11460818
53. Olsson J Lindberg G Gottsater M Lindwall K Sjostrand A Tisell A Melander A Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: A population-based observational study Diabetologia 2000, 43:558-560. 10855529
54. UK Diabetes Prospective Study (UKPDS) Group Effect of intensive blood-gucose control on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998, 352:854-865. 9742977
55. Rao AD Kuhadiya N Reynolds K Fonseca VA Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: A meta-analysis of observational studies Diabetes Care 2008, 31:1672-1678. 2494623 18458139
56. Fisman EZ Tenenbaum A Motro M Adler Y Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint Herz 2004, 29:290-298. 15167955
57. Fisman EZ Motro M Tenenbaum A Non-insulin antidiabetic therapy in cardiac patients: Current problems and future prospects Adv Cardiol 2008, 45:154-170. 18230961
58. Grundy SM Benjamin IJ Burke GL Chait A Eckel RH Howard BV Mitch W Smith SC Sowers JR Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association Circulation 1999, 100:1134-1146. 10477542
59. Gallwitz B The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions Rev Diabet Stud 2006, 3:208-216. 1828283 17487346
60. Kendall DM Cuddihy RM Bergenstal RM Clinical application of incretin-based therapy: Therapeutic potential, patient selection and clinical use Am J Med 2009, 122:S37-S50. 19464427
61. Unger RH Reinventing type 2 diabetes: Pathogenesis, treatment, and prevention JAMA 2008, 299:1185-1187. 18334695
62. Perley M Kipnis DM Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects J Clin Invest 1967, 46:1954-1962. 292948 6074000
63. Nauck MA Homberger E Siegel EG Allen RC Eaton RP Ebert R Creutzfeldt W Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 1986, 63:492-498. 3522621
64. Kreymann B Williams G Ghatei MA Bloom SR Glucagon-like peptide-1 7 36: A physiological incretin in man Lancet 1987, 2:1300-1304. 2890903
65. Efendic S Portwood N Overview of incretin hormones Horm Metab Res 2004, 36:742-746. 15655702
66. Creutzfeldt WO Kleine N Willms B Orskov C Holst JJ Nauck MA Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(736) amide in type I diabetic patients Diabetes Care 1996, 19:580-586. 8725855
67. Nauck MA Wollschlager D Werner J Holst JJ Orskov C Creutzfeldt W Willms B Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM Diabetologia 1996, 39:1546-1553. 8960841
68. Rachman J Barrow BA Levy JC Turner RC Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 1997, 40:205-211. 9049482
69. Zander M Madsbad S Madsen JL Holst JJ Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study Lancet 2002, 359:824-830. 11897280
70. Vilsboll T Holst JJ Incretins, insulin secretion and type 2 diabetes mellitus Diabetologia 2004, 47:357-366. 14968296
71. Nauck MA Baller B Meier JJ Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes Diabetes 2004, 53(suppl 3):S190-S196. 15561910
72. Deacon CF Circulation and degradation of GIP and GLP-1 Horm Metab Res 2004, 36:761-765. 15655705
73. Burcelin R The incretins: A link between nutrients and well-being Br J Nutrition 2005, 93(Suppl 1):S147-S156
74. Kendall DM Riddle MC Rosenstock J Zhuang D Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005, 28:1083-1091. 15855571
75. Mazze R Strock E Morgan B Wesley D Bergenstal R Cuddihy R Diurnal glucose patterns of exenatide once weekly: A 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis Endocr Pract 2009, 15:326-334. 19454385
76. Drucker DJ Buse JB Taylor K Kendall DM Trautmann M Zhuang D Porter L DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study Lancet 2008, 372:1240-1250. 18782641
77. Rolin B Larsen MO Gotfredsen CF The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice Am J Physiol Endocrinol Metab 2002, 283:E745-E752. 12217892
78. Agersø H Jensen LB Elbrønd B Rolan P Zdravkovic M The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 2002, 45:195-202. 11935150
79. Buse JB Rosenstock J Sesti G Schmidt WE Montanya E Brett JH Zychma M Blonde L LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009, 374:39-47. 19515413
80. Bush MA Matthews JE De Boever EH Dobbins RL Hodge RJ Walker SE Holland MC Gutierrez M Stewart MW Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects Diabetes Obes Metab 2009, 11:498-505. 19187286
81. Nauck MA Ratner RE Kapitza C Berria R Boldrin M Balena R Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: A double-blind placebo-controlled study Diabetes Care 2009, 32:1237-1243. 19366970
82. Drucker DJ The biology of incretin hormones Cell Metab 2006, 3:153-165. 16517403
83. Drucker DJ Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Expert Opin Invest Drugs 2003, 12:87-100.
84. Kim D Wang L Beconi M Eiermann GJ Fisher MH He H Hickey GJ Kowalchick JE Leiting B Lyons K Marsilio F McCann ME Patel RA Petrov A Scapin G Patel SB Roy RS Wu JK Wyvratt MJ Zhang BB Zhu L Thornberry NA Weber AE (2R)-4-oxo-4-[3-(trifluoromethyl) -5,6-dihydro [1,2,4]triazolo [4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluoro-phenyl) butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 2005, 48:141-151. 15634008
85. Moritoh Y Takeuchi K Asakawa T Kataoka O Odaka H The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice Eur J Pharmacol 2009, 602:448-54. 19038243
86. Bergman AJ Cote J Yi B Marbury T Swan SK Smith W Gottesdiener K Wagner J Herman GA Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor Diabetes Care 2007, 30:1862-1864. 17468348
87. Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes JAMA 2007, 298:194-206. 17622601
88. Tenenbaum A Motro M Fisman EZ Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons Cardiovasc Diabetol 2005, 4:14. 1236941 16168052
89. Tenenbaum A Fisman EZ Motro M Metabolic syndrome and type 2 diabetes mellitus: Focus on peroxisome proliferator activated receptors (PPAR) Cardiovasc Diabetol 2003, 2:4. 153546 12834541
90. Tenenbaum A Motro M Fisman EZ Tanne D Boyko V Behar S Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome Arch Intern Med 2005, 165:1154-1160. 15911729
91. Tenenbaum A Motro M Fisman EZ Schwammenthal E Adler Y Goldenberg I Leor J Boyko V Mandelzweig L Behar S Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease Circulation 2004, 109:2197-2202. 15123532
92. Tenenbaum A Motro M Fisman EZ Adler Y Shemesh J Tanne D Leor J Boyko V Schwammenthal E Behar S Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients Eur Heart J 2005, 26:2032-2038. 15872029
93. Hiuge A Tenenbaum A Maeda N Benderly M Kumada M Fisman EZ Tanne D Matas Z Hibuse T Fujita K Nishizawa H Adler Y Motro M Kihara S Shimomura I Behar S Funahashi T Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level Arterioscler Thromb Vasc Biol 2007, 27:635-641. 17194889
94. Tenenbaum H Behar S Boyko V Adler Y Fisman EZ Tanne D Lapidot M Schwammenthal E Feinberg M Matas Z Motro M Tenenbaum A Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes Atherosclerosis 2007, 194:265-271. 16970952
95. Tenenbaum A Fisman EZ Boyko V Benderly M Tanne D Haim M Matas Z Motro M Behar S Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate Arch Intern Med 2006, 166:737-741. 16606809
96. Kendall DM Rubin CJ Mohideen P Ledeine JM Belder R Gross J Norwood P O'Mahony M Sall K Sloan G Roberts A Fiedorek FT DeFronzo RA Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study Diabetes Care 2006, 29:1016-1023. 16644631
97. Henry RR Lincoff AM Mudaliar S Rabbia M Chognot C Herz M Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study Lancet 2009, 374:126-135. 19515415
98. Bénardeau A Benz J Binggeli A Blum D Boehringer M Grether U Hilpert H Kuhn B Märki HP Meyer M Püntener K Raab S Ruf A Schlatter D Mohr P Aleglitazar, a new, potent, and balanced dual PPAR alpha/gamma agonist for the treatment of type II diabetes Bioorg Med Chem Lett 2009, 19:2468-2473. 19349176
99. Inzucchi SE McGuire DK New drugs for the treatment of diabetes: Part II: Incretin-based therapy and beyond Circulation 2008, 117:574-584. 18227398
100. Levetan C Want LL Weyer C Strobel SA Crean J Wang Y Maggs DG Kolterman OG Chandran M Mudaliar SR Henry RR Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps Diabetes Care 2003, 26:1-8. 12502651
101. Bullock BP Heller RS Habener JF Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor Endocrinology 1996, 137:2968-2978. 8770921
102. Nikolaidis LA Elahi D Hentosz T Doverspike A Huerbin R Zourelias L Stolarski C Shen YT Shannon RP Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy Circulation 2004, 110:955-961. 15313949
103. Nikolaidis LA Mankad S Sokos GG Miske G Shah A Elahi D Shannon RP Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 2004, 109:962-965. 14981009
104. Giugliano D Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease? Curr Opinion Lipidol 1996, 7:227-233.
105. Tenenbaum A Fisman EZ Boyko V Goldbourt U Auerbach I Shemesh J Shotan A Reicher-Reiss H Behar S Motro M Prevalence and prognostic significance of unrecognized systemic hypertension in patients with diabetes mellitus and healed myocardial infarction and/or stable angina pectoris Am J Cardiol 1999, 84:294-298. 10496438
106. Tenenbaum A Fisman EZ Boyko V Goldbourt U Graff E Shemesh J Shotan A Reicher-Reiss H Behar S Motro M Hypertension in diet versus pharmacologically treated diabetics. Mortality over a 5-year follow-up Hypertension 1999, 33:1002-1007. 10205238
107. Tenenbaum A Motro M Fisman EZ Leor J Boyko V Mandelzweig L Behar S Status of glucose metabolism in patients with heart failure secondary to coronary artery disease Am J Cardiol 2002, 90:529-532. 12208417
108. Rodbard HW Blonde L Braithwaite SS Brett EM Cobin RH Handelsman Y Hellman R Jellinger PS Jovanovic LG Levy P Mechanick JI Zangeneh F AACE Diabetes Mellitus Clinical Practice Guidelines Task Force American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus Endocr Pract 2007, 13(Suppl 1):1-68. 17613449
109. Krentz AJ Clough G Byrne CD Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease? J Vasc Res 2009, 46:515-526. 19571572
110. Weiss IA Valiquette G Schwarcz MD Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes Cardiol Rev 2009, 17:165-175. 19525678